Beijing, China, Cambridge, Massachusetts, USA, and Basel, Switzerland—BeiGene (Nasdaq: BGNE; Hong Kong Stock Exchange: 06160; Shanghai Stock Exchange: 688235), a global biotechnology company, today announced that it has The commercialized products and new indications have been successfully entered into the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2023)" ("National Medical Insurance Drug Catalog") issued by the National Medical Insurance Administration ("National Medical Insurance Administration").

Among them, the company's independently developed anti-PD-1 antibody Zelzian® (tislelizumab injection) and BTK inhibitor Baiyezan® (zanubrutinib capsules) successfully renewed their contracts and added two new adaptations respectively. The disease was included in the national medical insurance drug catalog; the cooperative products introduced the long-acting goserelin microsphere preparation Bituowei® (goserelin microspheres for injection), the rare disease Castleman's disease treatment drug Savinco® (stuximab for injection) ) was included for the first time, while the RANKL inhibitor Anjiavir® (desomasumab injection, 120 mg (1.7ml)/bottle) was successfully converted into a regular Category B and a new indication was included. In addition, the company's independently developed PARP inhibitor Baihuize® (Pamiparib Capsules) was also successfully renewed this year.

“We are very excited that many of BeiGene’s innovative drugs and new indications have been successfully included in the National Medical Insurance Drug List, which will enable more domestic patients to use the world’s leading high-quality new anti-cancer drugs and effectively reduce the burden of treatment. In recent years, thanks to the in-depth reform of the medical insurance payment system and the rapid development of my country's innovative drug industry, many innovative drugs with clinical benefits can be included in medical insurance as soon as possible, greatly improving the accessibility and affordability of drugs for patients. "Dr. Wu Xiaobin, President and Chief Operating Officer of BeiGene, said, "Especially the strong support for Class 1 new drugs in this year's "Drug Renewal Negotiation Rules" reflects the National Medical Insurance Administration's policy orientation of encouraging innovation, which not only ensures patient treatment Demand has also laid a good foundation for the long-term development of the pharmaceutical industry. We believe that with the continuous improvement of the medical insurance system, the pharmaceutical industry will further move towards high-quality development and continue to benefit patients in my country and around the world."

The following are the products and indications newly added to the national medical insurance drug catalog this time or through renewal:

The contract of Bezian® was successfully renewed and two new indications were added to the National Medical Insurance Drug List:

Combination of fluorouracil and platinum chemotherapy is used as first-line treatment for locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma with high PD-L1 expression.
Combination of paclitaxel and platinum drugs or fluorouracil drugs and platinum drugs for the first-line treatment of unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma.
Baiyueze® was successfully renewed and two new indications were added to the National Medical Insurance Drug List:

Adult patients with newly diagnosed chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Adult patients with newly diagnosed Waldenstrom's macroglobulinemia (WM).
One indication of Bituowei® has been included in the National Medical Insurance Drug List:

Prostate cancer patients requiring androgen deprivation therapy.
One indication of Savinco® has been included in the National Medical Insurance Drug List:

Treatment of human immunodeficiency virus (HIV)-negative and human herpesvirus type 8 (HHV-8)-negative adult patients with multicentric Castleman disease (MCD).
Anjiawe® was successfully converted into a regular Category B and a new indication was included in the National Medical Insurance Drug List:

Treatment of patients with bone metastases from solid tumors or patients with multiple myeloma to delay or reduce the risk of bone-related events (pathological fractures, spinal cord compression, bone radiation therapy, or bone surgery).
Parkhuize® successfully renewed its contract:

Treatment of patients with recurrent advanced ovarian cancer, fallopian tube cancer or primary peritoneal cancer with germline BRCA (gBRCA) mutations who have received second-line or above chemotherapy.
The new version of the National Medical Insurance Drug Catalog will be officially implemented from January 1, 2024.

https://www.beigene.com.cn/pressreleases